+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Elidel"

Atopic Dermatitis Drugs Market - Forecasts from 2024 to 2029 - Product Thumbnail Image

Atopic Dermatitis Drugs Market - Forecasts from 2024 to 2029

  • Report
  • January 2024
  • 143 Pages
  • Global
From
From
From
  • 3 Results (Page 1 of 1)
Loading Indicator

Elidel is a topical cream used to treat atopic dermatitis, a chronic skin condition. It is a non-steroidal, anti-inflammatory drug (NSAID) that works by reducing inflammation and itching. Elidel is a brand name for the generic drug pimecrolimus, which is a calcineurin inhibitor. It is available in both cream and ointment form and is applied directly to the affected area. Elidel is typically used as a second-line treatment for atopic dermatitis, after topical corticosteroids have been tried and failed. Elidel is a relatively new drug, having been approved by the FDA in 2001. It is generally well-tolerated, with few side effects. However, it is not recommended for use in children under two years of age, due to the potential for increased risk of skin cancer. The Elidel market is a small but growing segment of the dermatological drugs market. It is primarily used to treat atopic dermatitis, but is also used to treat other skin conditions such as psoriasis and eczema. Companies in the Elidel market include Novartis, GlaxoSmithKline, and Pfizer. Show Less Read more